HK Stock Market Move | ABBIKO-B (02256) rises by more than 5%. The company announces the latest clinical developments of Ipgarginib and Pimintinib at the ESMO annual meeting.

ABBISKO-B (02256) is now up by over 5%, as of the sending of this report, it has increased by 5.59%, to 3.02 Hong Kong dollars, with a total turnover of 1.1619 million Hong Kong dollars. On the news front, Hoyo Pharmaceuticals announced that the company will present the latest clinical data on the safety and efficacy of its self-developed small molecule FGFR4 inhibitor, ipatroxanib (ABSK011), in phase I clinical trials targeting FGF19-overexpressing advanced hepatocellular carcinoma at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. In addition, the Phase II clinical study design of pimetinib in combination with chemotherapy and trastuzumab as first-line treatment for advanced pancreatic ductal adenocarcinoma will also be presented at this conference. The data released by the company shows that the ipatroxanib 220mg BID group demonstrated excellent efficacy in FGF19-overexpressing hepatocellular carcinoma patients treated with immune checkpoint inhibitors (ICIs) and multi-targeted small molecule tyrosine kinase inhibitors (mTKIs), with an overall response rate (ORR) of 44.8%, a median duration of response (mDOR) of 7.4 months, and a median progression-free survival (mPFS) of 5.5 months.